Treatment choices for diabetic macular oedema: a guideline for when to consider an intravitreal corticosteroid, including adaptations for the COVID-19 era | BMJ Open Ophthalmology
Diabetic macular edema treated with intravitreal aflibercept injection after treatment with other anti-VEGF agents (SWAP-TWO study): 6-month interim analysis | International Journal of Retina and Vitreous | Full Text
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema | NEJM
Eylea outperforms Avastin for diabetic macular edema with moderate or worse vision loss | National Institutes of Health (NIH)
Aflibercept for Diabetic Macular Edema: Seeing Dollar Signs - Clinical Advisor
A patient with diabetic macular edema who underwent intravitreal... | Download Scientific Diagram
Treatment of diabetic macular oedema | Eye News
Reduction of Diabetic Macular Edema in the Untreated Fellow Eye Following Intravitreal Injection of Aflibercept | Ophthalmic Surgery, Lasers and Imaging Retina
Diabetic Macular Edema—Personalizing Treatment - American Academy of Ophthalmology
Evidence-Based Guidelines for Management of Diabetic Macular Edema - Sophie J. Bakri, Jeremy D. Wolfe, Carl D. Regillo, Harry W. Flynn, Charles C. Wykoff, 2019
Regeneron shoots for longer Eylea dosing interval in diabetic retinopathy with NIH data | Fierce Pharma
Diabetic macular edema treated with intravitreal aflibercept injection after treatment with other anti-VEGF agents (SWAP-TWO study): 6-month interim analysis | International Journal of Retina and Vitreous | Full Text
No Visual Acuity Benefit With Early Anti-VEGF for Diabetic Retinopathy | MedPage Today
Anti-VEGF for the Management of Diabetic Macular Edema